Last reviewed · How we verify
LMX4
At a glance
| Generic name | LMX4 |
|---|---|
| Also known as | Placebo cream, LMX 4 (Lidocaine 4%) |
| Sponsor | Ferndale Laboratories, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison Study of LMX4 Cream Versus J-Tip Needle-Free Injection System With Lidocaine for In-Office PAT for Clubfoot (PHASE4)
- Occipital Blocks for Acute Migraine (PHASE3)
- Conservative Management of Cutaneous Abscess (PHASE4)
- "Lidocaine 4% Cream (LMX4) vs Placebo for Pain Due to Lumbar Puncture in Infants 0-60 Days of Age." (PHASE4)
- Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease (PHASE1)
- A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation (PHASE3)
- Comparing Bupivacaine, Lidocaine, and a Combination of Bupivacaine and Lidocaine for Labor Epidural Activation (PHASE3)
- Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LMX4 CI brief — competitive landscape report
- LMX4 updates RSS · CI watch RSS
- Ferndale Laboratories, Inc. portfolio CI